Lifileucel Shows Feasibility in Metastatic Sarcomas
A pilot trial found the cell therapy was infusible in most patients with advanced liposarcoma or pleomorphic sarcoma, with an early efficacy signal.
Updated on Nov. 8, 2026 in Cancer
Investigators presented feasibility findings from a phase 1 pilot trial of lifileucel, a tumor-infiltrating lymphocyte therapy, in patients with metastatic or unresectable dedifferentiated liposarcoma or undifferentiated pleomorphic sarcoma. The trial met its feasibility end point, with 11 of 13 patients who underwent surgery infused.
Why it matters
Advanced sarcomas have limited treatment options after systemic therapy, so a feasible cell-based approach could expand what clinicians can offer these patients. The early efficacy signal provides a rationale for a larger, formal evaluation.
The pilot enrolled patients after at least one prior line of systemic therapy, and 11 of 13 surgically treated patients were infused, meeting the feasibility end point of six of the first ten. Efficacy was not a primary aim, so the emerging signal in a small number of patients is not yet characterized in size or duration.
The players
Memorial Sloan Kettering Cancer Center
A New York-based cancer center whose investigators led the presentation of the lifileucel pilot findings.
SITC Annual Meeting
The Society for Immunotherapy of Cancer's annual scientific meeting, where the feasibility findings were presented in 2026.
The details
Patients underwent surgical tumor harvest, then lymphodepleting chemotherapy, followed by lifileucel infusion and interleukin-2. Two patients received out-of-specification product after shared risk-benefit discussions with the study team and the patients.
Timeline
The findings were presented at the 2026 SITC Annual Meeting.
The multicenter phase 2 SARATOGA trial will follow to evaluate efficacy.
Health Landscape
Tumor-infiltrating lymphocyte therapy was first validated in advanced melanoma, and this pilot extends that cell-based approach into sarcomas, which have historically had few effective options after initial systemic treatment. Whether the approach translates beyond melanoma will depend on the forthcoming phase 2 efficacy data.
For patients with advanced sarcoma who have already received systemic therapy, this trial signals a possible future option, though it is not yet available outside research settings. Patients considering trial enrollment should discuss eligibility and the surgical and chemotherapy steps involved with their oncologist.
The takeaway
Early feasibility is a necessary step before efficacy can be judged, and the coming phase 2 trial will determine whether the signal seen in a few patients holds. Readers should treat these results as promising but preliminary.
What happens next
The multicenter phase 2 SARATOGA trial (NCT07741877) will formally evaluate lifileucel efficacy in these sarcoma populations.
Further reading
Explore more cancer research and treatment news to see how cell-based therapies are advancing across tumor types.
Source note: This article includes information reported by OncLive.
